{
    "nctId": "NCT04066335",
    "briefTitle": "Study to Evaluate the Safety of Nanoxel M Inj.",
    "officialTitle": "An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1498,
    "primaryOutcomeMeasure": "Safety of Nanoxel M inj.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults \u226518 years old\n2. Patients who have signed written consent form prior to participating in the clinical trial\n3. Patients who are assessed as adequate to administer Nanoxel M injection.\n\nExclusion Criteria:\n\n1) Patients who have shown severe hypersensitivity to Docetaxel and concomitant drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}